Evidence map›Paper›PMID 39126505›Full record

ArticleAnalytical and bioanalytical chemistry2024

Novel mimetic tissue standards for precise quantitative mass spectrometry imaging of drug and neurotransmitter concentrations in rat brain tissues.

Kenichi Watanabe, Sayo Takayama, Toichiro Yamada, Masayo Hashimoto, Jun Tadano, Tetsuya Nakagawa, Takao Watanabe, Eiichiro Fukusaki, Izuru Miyawaki, Shuichi Shimma

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenichi WatanabePreclinical Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Sayo TakayamaPreclinical Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Toichiro YamadaPreclinical Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Masayo HashimotoPreclinical Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Jun TadanoResearch Planning & Coordination, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Tetsuya NakagawaResearch Planning & Coordination, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Takao WatanabeDrug Research Division, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Eiichiro FukusakiDepartment of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, 565-0871, Japan.
Izuru MiyawakiPreclinical Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Shuichi ShimmaDepartment of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, 565-0871, Japan. sshimma@bio.eng.osaka-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the relationship between the concentration of a drug and its therapeutic efficacy or side effects is crucial in drug development, especially to understand therapeutic efficacy in central nervous system drug, quantifying drug-induced site-specific changes in the levels of endogenous metabolites, such as neurotransmitters. In recent times, evaluation of quantitative distribution of drugs and endogenous metabolites using matrix-assisted laser desorption/ionization (MALDI)-mass spectrometry imaging (MSI) has attracted much attention in drug discovery research. However, MALDI-MSI quantification (quantitative mass spectrometry imaging, QMSI) is an emerging technique, and needs to be further developed for practicable and convenient use in drug discovery research. In this study, we developed a reliable QMSI method for quantification of clozapine (antipsychotic drug) and dopamine and its metabolites in the rat brain using MALDI-MSI. An improved mimetic tissue model using powdered frozen tissue for QMSI was established as an alternative method, enabling the accurate quantification of clozapine levels in the rat brain. Furthermore, we used the improved method to evaluate drug-induced fluctuations in the concentrations of dopamine and its metabolites. This method can quantitatively evaluate drug localization in the brain and drug-induced changes in the concentration of endogenous metabolites, demonstrating the usefulness of QMSI.

Indexed as

BrainClozapineNeurotransmitter AgentsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAnimalsAntipsychotic AgentsBrain ChemistryDopamineMaleRatsRats, Sprague-DawleyAntipsychotic AgentsClozapineDopamineNeurotransmitter AgentsBrainClozapineMatrix-assisted laser desorption/ionizationNeurotransmittersQuantitative mass spectrometry imaging

Identifiers

PMID39126505
PMCPMC11493812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.